Peterson Jennifer K, Setty Shaun P, Knight Jessica H, Thomas Amanda S, Moller James H, Kochilas Lazaros K
Children's Heart Institute, MemorialCare Miller Children's and Women's Hospital, Long Beach, California.
Memorial Heart and Vascular Institute, Long Beach Memorial Medical Center, Long Beach, California.
Congenit Heart Dis. 2019 Sep;14(5):854-863. doi: 10.1111/chd.12823. Epub 2019 Jul 22.
Patients with Trisomy 21 (T21) and single ventricle (SV) physiology present unique challenges compared to euploidic counterparts. This study reports postoperative and long-term outcomes in patients with T21 and SV palliation.
This retrospective cohort study from the Pediatric Cardiac Care Consortium (PCCC) included patients with T21 (<21 years old) that underwent surgical palliation for SV between 1982 and 2008 and control patients without known genetic anomaly following Fontan palliation for similar diagnoses. Kaplan-Meier survival plots were created based on death events obtained from the PCCC and by linkage with the National Death Index (NDI) and the Organ Procurement and Transplantation Network (OPTN) through 2014 for patients with adequate identifiers.
We identified 118 children with T21 who underwent initial surgical SV palliation. Among 90 (75.6%) patients surviving their first surgery, 66 (73.3%) underwent Glenn anastomosis and 25 (27.8%) completed Fontan palliation with in-hospital survival of 80.3% and 76.0%, respectively. Fifty-three patients had sufficient identifiers for PCCC-NDI-OPTN linkage. Ten-year survival, conditioned on discharge alive after the Fontan procedure, was 66.7% compared to 92.2% for 51 controls without genetic anomaly (P = .001). Median age at death for T21 patients following initial surgical SV palliation was 2.69 years (IQR 1.34-7.12) with most deaths (89.2%) attributed to the underlying congenital heart disease (CHD).
Children with T21 and SV are at high risk for procedural and long-term mortality related to their genetic condition and underlying CHD. Nevertheless, a select group of patients can successfully complete Glenn or Fontan palliation, reaching satisfactory long-term survival.
与染色体数目正常的患者相比,21三体综合征(T21)合并单心室(SV)生理状况的患者面临着独特的挑战。本研究报告了T21合并SV姑息治疗患者的术后及长期预后情况。
这项来自儿科心脏护理联盟(PCCC)的回顾性队列研究纳入了1982年至2008年间接受SV手术姑息治疗的T21患者(<21岁),以及因类似诊断接受Fontan姑息治疗且无已知遗传异常的对照患者。根据从PCCC获得的死亡事件,并通过与国家死亡指数(NDI)和器官获取与移植网络(OPTN)进行关联,为有足够标识符的患者创建了Kaplan-Meier生存曲线,随访至2014年。
我们确定了118例接受初次SV手术姑息治疗的T21患儿。在首次手术存活的90例(75.6%)患者中,66例(73.3%)接受了Glenn吻合术,25例(27.8%)完成了Fontan姑息治疗,住院生存率分别为80.3%和76.0%。53例患者有足够的标识符用于PCCC-NDI-OPTN关联。Fontan手术后存活出院的患者10年生存率为66.7%,而51例无遗传异常的对照患者为92.2%(P = 0.001)。初次SV手术姑息治疗后T21患者的中位死亡年龄为2.69岁(四分位间距1.34 - 7.12),大多数死亡(89.2%)归因于潜在的先天性心脏病(CHD)。
T21合并SV的儿童因其遗传状况和潜在的CHD,在手术及长期死亡率方面风险较高。然而,一部分患者能够成功完成Glenn或Fontan姑息治疗,实现令人满意的长期生存。